{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T22:44:00Z","timestamp":1787352240945,"version":"build-2736575974"},"reference-count":96,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1253\/circj.cj-13-1263","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T23:06:48Z","timestamp":1384297608000},"page":"4-11","source":"Crossref","is-referenced-by-count":56,"title":["Assessment of Operability of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease"],"prefix":"10.1253","volume":"78","author":[{"given":"Patrick O.","family":"Myers","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Surgery, Geneva University Hospitals & School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tissot","sequence":"additional","affiliation":[{"name":"Unit of Pediatric Cardiology, University Children\u2019s Hospital & School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Beghetti","sequence":"additional","affiliation":[{"name":"Unit of Pediatric Cardiology, University Children\u2019s Hospital & School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":" 1. Beghetti M, Galie N, Bonnet D. Can “inoperable” congenital heart defects become operable in patients with pulmonary arterial hypertension? Dream or reality? Congenit Heart Dis 2012; 7: 3–11.","DOI":"10.1111\/j.1747-0803.2011.00611.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":" 2. Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008; 129: 163–171.","DOI":"10.1016\/j.ijcard.2008.02.004"},{"key":"3","unstructured":" 3. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493–2537."},{"key":"4","doi-asserted-by":"crossref","unstructured":" 4. Balint OH, Samman A, Haberer K, Tobe L, McLaughlin P, Siu SC, et al. Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure. Heart 2008; 94: 1189–1193.","DOI":"10.1136\/hrt.2006.114660"},{"key":"5","doi-asserted-by":"crossref","unstructured":" 5. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: The UK Pulmonary Hypertension Service for Children 2001–2006. Heart 2009; 95: 312–317.","DOI":"10.1136\/hrt.2008.150086"},{"key":"6","doi-asserted-by":"crossref","unstructured":" 6. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features of paediatric pulmonary hypertension: A registry study. Lancet 2012; 379: 537–546.","DOI":"10.1016\/S0140-6736(11)61621-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":" 7. Gatzoulis MA, Alonso-Gonzalez R, Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009; 18: 154–161.","DOI":"10.1183\/09059180.00003309"},{"key":"8","doi-asserted-by":"crossref","unstructured":" 8. Gupta H, Ghimire G, Naeije R. The value of tools to assess pulmonary arterial hypertension. Eur Respir Rev 2011; 20: 222–235.","DOI":"10.1183\/09059180.00006911"},{"key":"9","doi-asserted-by":"crossref","unstructured":" 9. Frescura C, Thiene G, Giulia Gagliardi M, Mazzucco A, Pellegrino PA, Daliento L, et al. Is lung biopsy useful for surgical decision making in congenital heart disease? Eur J Cardiothorac Surg 1991; 5: 118–122; discussion: 122–123.","DOI":"10.1016\/1010-7940(91)90209-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Viswanathan S, Kumar RK. Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. Catheter Cardiovasc Interv 2008; 71: 665–670.","DOI":"10.1002\/ccd.21446"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lopes AA, O’Leary PW. Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 2009; 19: 431–435.","DOI":"10.1017\/S1047951109990771"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Giglia TM, Humpl T. Preoperative pulmonary hemodynamics and assessment of operability: Is there a pulmonary vascular resistance that precludes cardiac operation? Pediatr Crit Care Med 2010; 11(2 Suppl): S57–S69.","DOI":"10.1097\/PCC.0b013e3181d10cce"},{"key":"13","unstructured":"13. Kannan BR, Sivasankaran S, Tharakan JA, Titus T, Ajith Kumar VK, Francis B, et al. Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. Indian Heart J 2003; 55: 161–166."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Constantine G, Shan K, Flamm SD, Sivananthan MU. Role of MRI in clinical cardiology. Lancet 2004; 363: 2162–2171.","DOI":"10.1016\/S0140-6736(04)16509-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 2004; 25: 1940–1965.","DOI":"10.1016\/j.ehj.2004.06.040"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Laffon E, Vallet C, Bernard V, Montaudon M, Ducassou D, Laurent F, et al. A computed method for noninvasive MRI assessment of pulmonary arterial hypertension. J Appl Physiol 2004; 96: 463–468.","DOI":"10.1152\/japplphysiol.00292.2003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Roeleveld RJ, Marcus JT, Boonstra A, Postmus PE, Marques KM, Bronzwaer JG, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. J Magn Reson Imag 2005; 22: 67–72.","DOI":"10.1002\/jmri.20338"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, Bronzwaer JG, Marques KM, Postmus PE, et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest 2004; 125: 572–579.","DOI":"10.1378\/chest.125.2.572"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chin KM, Kingman M, de Lemos JA, Warner JJ, Reimold S, Peshock R, et al. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. Am J Cardiol 2008; 101: 1669–1672.","DOI":"10.1016\/j.amjcard.2008.01.055"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171: 1292–1297.","DOI":"10.1164\/rccm.200410-1411OC"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. van Wolferen SA, Boonstra A, Marcus JT, Marques KM, Bronzwaer JG, Postmus PE, et al. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. Heart 2006; 92: 1860–1861.","DOI":"10.1136\/hrt.2005.085118"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Blalock SE, Matulevicius S, Mitchell LC, Reimold S, Warner J, Peshock R, et al. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail 2010; 16: 121–127.","DOI":"10.1016\/j.cardfail.2009.09.008"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066–2069.","DOI":"10.1161\/01.CIR.0000099502.17776.C2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Taniguchi Y, Emoto N, Miyagawa K, Nakayama K, Kinutani H, Tanaka H, et al. Noninvasive and simple assessment of cardiac output and pulmonary vascular resistance with whole-body impedance cardiography is useful for nonitoring patients with pulmonary hypertension. Circ J 2013; 77: 2383–2389.","DOI":"10.1253\/circj.CJ-13-0172"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Lock JE, Einzig S, Bass JL, Moller JH. The pulmonary vascular response to oxygen and its influence on operative results in children with ventricular septal defect. Pediatr Cardiol 1982; 3: 41–46.","DOI":"10.1007\/BF02082331"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Berner M, Beghetti M, Spahr-Schopfer I, Oberhansli I, Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996; 77: 532–535.","DOI":"10.1016\/S0002-9149(97)89353-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, et al. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): The INOP Test Study Group. Circulation 2002; 106(12 Suppl 1): I76–I81.","DOI":"10.1161\/01.cir.0000032875.55215.cb"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865–870.","DOI":"10.1161\/01.CIR.102.8.865"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313–1321.","DOI":"10.1378\/chest.129.5.1313"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844–848.","DOI":"10.1161\/01.CIR.0000084544.54513.E2"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 487–492.","DOI":"10.1164\/ajrccm.160.2.9812078"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70–75.","DOI":"10.1056\/NEJM199207093270202"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W, et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005; 19: 1175–1177.","DOI":"10.1096\/fj.04-3223fje"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005; 25: 1414–1418.","DOI":"10.1161\/01.ATV.0000168414.06853.f0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562–1569.","DOI":"10.1378\/chest.120.5.1562"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Montani D, Souza R, Binkert C, Fischli W, Simonneau G, Clozel M, et al. Endothelin-1\/endothelin-3 ratio: A potential prognostic factor of pulmonary arterial hypertension. Chest 2007; 131: 101–108.","DOI":"10.1378\/chest.06-0682"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosenzweig EB, Barst RJ. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 2005; 128: 2355–2362.","DOI":"10.1378\/chest.128.4.2355"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Lopes AA, Maeda NY. Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Chest 1998; 114: 1276–1282.","DOI":"10.1378\/chest.114.5.1276"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628–1631.","DOI":"10.1164\/ajrccm.151.5.7735624"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Itoh T, Nagaya N, Ishibashi-Ueda H, Kyotani S, Oya H, Sakamaki F, et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006; 11: 158–163.","DOI":"10.1111\/j.1440-1843.2006.00821.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010; 122: 920–927.","DOI":"10.1161\/CIRCULATIONAHA.109.933762"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Lorenzen JM, Nickel N, Kramer R, Golpon H, Westerkamp V, Olsson KM, et al. Osteopontin in patients with idiopathic pulmonary hypertension. Chest 2011; 139: 1010–1017.","DOI":"10.1378\/chest.10-1146"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: A new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211–1218.","DOI":"10.1016\/j.jacc.2008.12.038"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 534–541.","DOI":"10.1164\/rccm.200802-235OC"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 1038–1042.","DOI":"10.1164\/ajrccm.164.6.2104033"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pibarot P, Bonnet S, et al. Pim-1: A new biomarker in pulmonary arterial hypertension. Pulm Circ 2013; 3: 74–81.","DOI":"10.4103\/2045-8932.109917"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Belly MJ, Tiede H, Morty RE, Schulz R, Voswinckel R, Tanislav C, et al. HbA1c in pulmonary arterial hypertension: A marker of prognostic relevance? J Heart Lung Transplant 2012; 31: 1109–1114.","DOI":"10.1016\/j.healun.2012.08.014"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Smadja DM, Gaussem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S, et al. Circulating endothelial cells: A new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009; 119: 374–381.","DOI":"10.1161\/CIRCULATIONAHA.108.808246"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Rhodes CJ, Wharton J, Boon RA, Roexe T, Tsang H, Wojciak-Stothard B, et al. Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013; 187: 294–302.","DOI":"10.1164\/rccm.201205-0839OC"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Wei C, Henderson H, Spradley C, Li L, Kim IK, Kumar S, et al. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One 2013; 8: e64396, doi:10.1371\/journal.pone.0064396.","DOI":"10.1371\/journal.pone.0064396"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Levy M, Maurey C, Celermajer DS, Vouhé PR, Danel C, Bonnet D, et al. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 2007; 49: 803–810.","DOI":"10.1016\/j.jacc.2006.09.049"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Levy M, Bonnet D, Mauge L, Celermajer DS, Gaussem P, Smadja DM. Circulating endothelial cells in refractory pulmonary hypertension in children: Markers of treatment efficacy and clinical worsening. PLoS One 2013; 8: e65114, doi:10.1371\/journal.pone.0065114.","DOI":"10.1371\/journal.pone.0065114"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Smadja DM, Gaussem P, Mauge L, Lacroix R, Gandrille S, Remones V, et al. Comparison of endothelial biomarkers according to reversibility of pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 2010; 31: 657–662.","DOI":"10.1007\/s00246-010-9674-0"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Boettger T, Braun T. A new level of complexity: The role of microRNAs in cardiovascular development. Circ Res 2012; 110: 1000–1013.","DOI":"10.1161\/CIRCRESAHA.111.247742"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007; 101: 1225–1236.","DOI":"10.1161\/CIRCRESAHA.107.163147"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F. microRNAs as peripheral blood biomarkers of cardiovascular disease. Vascul Pharmacol 2011; 55: 111–118.","DOI":"10.1016\/j.vph.2011.08.001"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009; 55: 1944–1949.","DOI":"10.1373\/clinchem.2009.125310"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009; 4: e5532, doi:10.1371\/journal.pone.0005532.","DOI":"10.1371\/journal.pone.0005532"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659–666.","DOI":"10.1093\/eurheartj\/ehq013"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Gidlof O, Andersson P, van der Pals J, Gotberg M, Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011; 118: 217–226.","DOI":"10.1159\/000328869"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: A comparison between clinical subgroups. Eur Heart J 2013 March 1, doi:10.1093\/eurheartj\/eht072.","DOI":"10.1093\/eurheartj\/eht072"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr 2010; 157: 528–532.","DOI":"10.1016\/j.jpeds.2010.06.010"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48–54.","DOI":"10.1161\/CIRCULATIONAHA.106.630715"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Budts W, Van Pelt N, Gillyns H, Gewillig M, Van De Werf F, Janssens S. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart 2001; 86: 553–558.","DOI":"10.1136\/heart.86.5.553"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 2003; 107: 1329–1335.","DOI":"10.1161\/01.CIR.0000053443.27512.33"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Theo Schermuly R, Ardeschir Ghofrani H, Weissmann N. Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension. Curr Top Dev Biol 2005; 67: 251–284.","DOI":"10.1016\/S0070-2153(05)67008-1"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001; 358: 1119–1123.","DOI":"10.1016\/S0140-6736(01)06250-X"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903.","DOI":"10.1056\/NEJMoa012212"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet 2008; 371: 2093–2100.","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–2157.","DOI":"10.1056\/NEJMoa050010"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049–2056.","DOI":"10.1016\/j.jacc.2006.01.057"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Gatzoulis MA, Beghetti M, Galie N, Granton J, Berger RM, Lauer A, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. Int J Cardiol 2008; 127: 27–32.","DOI":"10.1016\/j.ijcard.2007.04.078"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Berger RM, Beghetti M, Galie N, Gatzoulis MA, Granton J, Lauer A, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger’s syndrome: A subgroup analysis. Int J Cardiol 2010; 144: 373–378.","DOI":"10.1016\/j.ijcard.2009.04.037"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858–1865.","DOI":"10.1161\/01.CIR.99.14.1858"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Hirabayashi A, Miyaji K, Akagi T. Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension. Catheter Cardiovasc Interv 2009; 73: 688–691.","DOI":"10.1002\/ccd.21877"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Hoetzenecker K, Ankersmit HJ, Bonderman D, Hoetzenecker W, Seitelberger R, Klepetko W, et al. Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: A case report. J Thorac Cardiovasc Surg 2009; 137: 760–761.","DOI":"10.1016\/j.jtcvs.2008.03.064"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Mitropoulos FA, Apostolopoulou SC, Kanakis MA, Rammos S, Anagnostopoulos CE. Bosentan treatment in an adult with pulmonary hypertension due to patent ductus arteriosus permits surgical repair. J Heart Lung Transplant 2007; 26: 1345–1346.","DOI":"10.1016\/j.healun.2007.09.001"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Ussia GP, Mule M, Caruso E, Aiello R, Tamburino C. Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension. Int J Cardiol 2007; 116: 427–429.","DOI":"10.1016\/j.ijcard.2006.03.080"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with “irreversible” pulmonary hypertensive arteriopathy. Int J Cardiol 2006; 110: 104–107.","DOI":"10.1016\/j.ijcard.2005.05.062"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Frost AE, Quinones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005; 24: 501–503.","DOI":"10.1016\/j.healun.2004.02.004"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Kim YH, Yu JJ, Yun TJ, Lee Y, Kim YB, Choi HS, et al. Repair of atrial septal defect with Eisenmenger syndrome after long-term sildenafil therapy. Ann Thorac Surg 2010; 89: 1629–1630.","DOI":"10.1016\/j.athoracsur.2009.10.027"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Gatzoulis MA, Giannakoulas G. Sinus venosus atrial septal defect in a 31-year-old female patient: A case for surgical repair. Eur Respir Rev 2010; 19: 340–344.","DOI":"10.1183\/09059180.00007610"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Beghetti M, Tissot C. Pulmonary arterial hypertension and congenital heart disease: Targeted therapies and operability. J Thorac Cardiovasc Surg 2009; 138: 785–786.","DOI":"10.1016\/j.jtcvs.2009.04.034"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005; 16: 19–25.","DOI":"10.1097\/00019501-200502000-00004"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Hall SM, Haworth SG. Onset and evolution of pulmonary vascular disease in young children: Abnormal postnatal remodelling studied in lung biopsies. J Pathol 1992; 166: 183–193.","DOI":"10.1002\/path.1711660216"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Huang JB, Liang J, Zhou LY. Eisenmenger syndrome: Not always inoperable. Respir Care 2012; 57: 1488–1495.","DOI":"10.4187\/respcare.01418"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19: 1845–1855.","DOI":"10.1053\/euhj.1998.1046"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, et al. Exercise intolerance in adult congenital heart disease: Comparative severity, correlates, and prognostic implication. Circulation 2005; 112: 828–835.","DOI":"10.1161\/CIRCULATIONAHA.104.529800"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Novick WM, Sandoval N, Lazorhysynets VV, Castillo V, Baskevitch A, Mo X, et al. Flap valve double patch closure of ventricular septal defects in children with increased pulmonary vascular resistance. Ann Thorac Surg 2005; 79: 21–28; discussion: 21–28.","DOI":"10.1016\/j.athoracsur.2004.06.107"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Nishimura R, Tanabe N, Sugiura T, Shigeta A, Jujo T, Sekine A, et al. Improved survival in medically treated chronic thromboembolic pulmonary hypertension. Circ J 2013; 77: 2110–2117.","DOI":"10.1253\/circj.CJ-12-1391"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Ghofrani HA, Galie N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330–340.","DOI":"10.1056\/NEJMoa1209655"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Thomas IC, Glassner-Kolmin C, Gomberg-Maitland M. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease. Int J Cardiol 2013; 168: 4117–4121.","DOI":"10.1016\/j.ijcard.2013.07.072"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart 2005; 91: 1447–1452.","DOI":"10.1136\/hrt.2004.051961"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120: 301–305.","DOI":"10.1016\/j.ijcard.2006.10.018"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Fernandes SM, Newburger JW, Lang P, Pearson DD, Feinstein JA, Gauvreau K, et al. Usefulness of epoprostenol therapy in the severely ill adolescent\/adult with Eisenmenger physiology. Am J Cardiol 2003; 91: 632–635.","DOI":"10.1016\/S0002-9149(02)03328-3"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, et al. Double-blind, placebo-controlled clinical trial with a Rho-Kinase inhibitor in pulmonary arterial hypertension. Circ J 2013; 77: 2619–2625.","DOI":"10.1253\/circj.CJ-13-0443"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/78\/1\/78_CJ-13-1263\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T12:30:36Z","timestamp":1688646636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/78\/1\/78_CJ-13-1263\/_article"}},"subtitle":["\u2013 Do We Have the Good Tools to Predict Success? \u2013"],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-13-1263","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}